Donna M. Graham
YOU?
Author Swipe
View article: UpSMART: five years of digital innovation in cancer clinical research—achievements, challenges, and recommendations
UpSMART: five years of digital innovation in cancer clinical research—achievements, challenges, and recommendations Open
UpSMART, a research programme involving 24 European cancer centres, aimed to promote digital innovation in early-phase clinical research addressing challenges in recruitment, data collection and analysis. Several open-source digital health…
View article: Patient and Clinician Perspectives on the Communication of Genomic Results in Cancer Care
Patient and Clinician Perspectives on the Communication of Genomic Results in Cancer Care Open
Purpose Patients diagnosed with advanced cancer are increasingly being offered comprehensive genomic profiling (CGP) to determine whether they are eligible for biomarker‐informed treatment. The communication of CGP results to patients can …
View article: Circulating Tumor DNA as a Prognostic Biomarker for Selecting Participants to Early Phase Clinical Trials
Circulating Tumor DNA as a Prognostic Biomarker for Selecting Participants to Early Phase Clinical Trials Open
Introduction Patients with advanced solid tumors may be considered for early phase clinical trials investigating the safety, tolerability, and dosing of experimental therapies. Optimizing participant selection is critical to maximize clini…
View article: Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial.
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial. Open
PURPOSE: This multicenter phase II basket trial investigated the efficacy, safety and pharmacokinetics of Debio 1347, an investigational, oral, highly selective, ATP-competitive, small molecule inhibitor of FGFR1-3, in patients with solid …
View article: Translating the machine; An assessment of clinician understanding of ophthalmological artificial intelligence outputs
Translating the machine; An assessment of clinician understanding of ophthalmological artificial intelligence outputs Open
Clinicians' trust in AI algorithms are affected by explainability methods and factors, including AI's performance, personal judgments and clinical experience. The development of clinical AI systems should consider the above and these respo…
View article: Supplementary Table S8 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S8 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial Open
Supplementary Table S8. Progression-free survival according to local assessment (intention-to-treat population).
View article: Supplementary Table S3 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S3 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial Open
Supplementary Table S3. FGFR1–3 fusions partners detected in a large pan-tumor database of Caris Life Sciences (Phoenix, AZ) using whole-transcriptome sequencing.
View article: Supplementary Table S12 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S12 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial Open
Supplementary Table S12. Grade ≥3 treatment-emergent adverse events considered by the investigator to be related to the study drug (safety population).
View article: Supplementary Table S11 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S11 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial Open
Supplementary Table S11. Treatment-emergent adverse events occurring at grade ≥3 in ≥2 patients (safety population).
View article: Supplementary Table S4 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S4 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial Open
Supplementary Table S4. Baseline characteristics and outcomes of patients in the intention-to-treat population with response according to central review.
View article: Supplementary Methods S1 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Methods S1 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial Open
Supplementary methods
View article: Supplementary Table S2 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S2 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial Open
Supplementary Table S2. Tissue source for FGFR fusion determination (intention-to-treat population).
View article: Supplementary Figure S2 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Figure S2 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial Open
Supplementary Figure S2. Progression-free survival.
View article: Data from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Data from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial Open
Purpose:This multicenter phase II basket trial investigated the efficacy, safety, and pharmacokinetics of Debio 1347, an investigational, oral, highly selective, ATP-competitive, small molecule inhibitor of FGFR1–3, in patients with solid …
View article: Supplementary Table S7 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S7 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial Open
Supplementary Table S7. Progression-free survival according to central review (intention-to-treat population).
View article: Supplementary Table S5 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S5 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial Open
Supplementary Table S5. Response and disease control according to local assessment (intention-to-treat population).
View article: Supplementary Table S6 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S6 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial Open
Supplementary Table S6. Response according to central review (modified intention-to-treat population).
View article: Supplementary Table S13 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S13 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial Open
Supplementary Table S13. Serious adverse events occurring in ≥2 patients (safety population).
View article: Supplementary Table S9 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S9 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial Open
Supplementary Table S9. Summary of adverse events (safety population).
View article: Supplementary Table S1 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S1 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial Open
Supplementary Table S1. Representativeness of study participants.
View article: Supplementary Figure S1 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Figure S1 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial Open
Supplementary Figure S1. Study CONSORT diagram.
View article: Supplementary Table S10 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S10 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial Open
Supplementary Table S10. Treatment-emergent adverse events considered by the investigator to be related to the study drug occurring at any grade in ≥10% of patients (safety population).
View article: Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based population
Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based population Open
Aim: Renal cell carcinoma (RCC) is the seventh commonest cancer in the UK, where first-line (1L) sunitinib and second-line (2L) axitinib are treatment options.Methods: Retrospective, non-interventional data from the Christie NHS Foundation…
View article: Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study
Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study Open
Background Novel treatments are needed for patients with advanced, triple‐negative breast cancer (TNBC) that progresses or recurs after first‐line treatment with chemotherapy. The authors report results from the TNBC cohort of the multicoh…